The Tetrad BMI, Leptin, Leptin/Adiponectin (L/A) Ratio and CA-15-3 is a Reliable Biomarker of Breast Cancer
leptin
Phase 1. Collect Samples of Breast Biopsy Patients Treated at the Hospital Radiology Service Maternal Perinatal Monica Pretelini
1 other identifier
observational
88
0 countries
N/A
Brief Summary
Objective: Evaluate body mass index (BMI), leptin, Leptin/adiponectin (L/A) ratio and cancer antigen (CA) 15-3 together as reliable biomarkers for breast cancer. Patients: Consecutive patients aged between 40 - 60 years, with breast disease and informed consent. Interventions: Patients' Anthropometric and laboratorial characteristics classified by BMI in the group of cancer and patients with benign breast disease as well as biochemical tests of leptin, adiponectin,CA 15-3, hemoglobin, glucose low-density lipoprotein cholesterol (LDLC), high-density lipoprotein cholesterol (HDLC) levels were obtained as well as a blood sample to analyze CA 15-3 levels with a electrochemiluminescence immunoassay. Hypothesis: Using together leptin, L/A ratio, CA 15-3 and BMI could offer a reliable approach to detect high risk women to develop breast cancer.
Trial Health
Trial Health Score
Automated assessment based on enrollment pace, timeline, and geographic reach
participants targeted
Target at P50-P75 for all trials
Started Jan 2011
Health score is calculated from publicly available data and should be used for screening purposes only.
Trial Relationships
Click on a node to explore related trials.
Study Timeline
Key milestones and dates
Study Start
First participant enrolled
January 1, 2011
CompletedPrimary Completion
Last participant's last visit for primary outcome
October 1, 2011
CompletedStudy Completion
Last participant's last visit for all outcomes
July 1, 2012
CompletedFirst Submitted
Initial submission to the registry
July 16, 2012
CompletedFirst Posted
Study publicly available on registry
July 18, 2012
CompletedJuly 18, 2012
July 1, 2012
9 months
July 16, 2012
July 17, 2012
Conditions
Keywords
Study Arms (2)
breast cancer patients (cases)
36 subjects
controls
36 subjects
Eligibility Criteria
Cross-sectional prospective study conducted at the Maternal-Perinatal Hospital "Mónica Pretelini" (HMPMP), State of Mexico Health Institute (ISEM), Toluca, Mexico, from January to October 2011.
You may qualify if:
- Female patients attending mammography, average age of the fourth and fifth decades.
You may not qualify if:
- Patients with hormonal therapy.
Contact the study team to confirm eligibility.
Sponsors & Collaborators
Related Publications (1)
Santillan-Benitez JG, Mendieta-Zeron H, Gomez-Olivan LM, Torres-Juarez JJ, Gonzalez-Banales JM, Hernandez-Pena LV, Ordonez-Quiroz A. The tetrad BMI, leptin, leptin/adiponectin (L/A) ratio and CA 15-3 are reliable biomarkers of breast cancer. J Clin Lab Anal. 2013 Jan;27(1):12-20. doi: 10.1002/jcla.21555. Epub 2013 Jan 4.
PMID: 23292756DERIVED
Biospecimen
serum
MeSH Terms
Conditions
Condition Hierarchy (Ancestors)
Study Officials
- PRINCIPAL INVESTIGATOR
Jonnathan Guadalupe Santillán Benítez, MSc
Autonomus University Of the State Of México
- STUDY DIRECTOR
Leobardo Manuel Gómez Oliván, PhD
Universidad Autonoma del Estado de Mexico
- STUDY CHAIR
Hugo Mendieta Zeron, PhD
Autonomous University of the State of Mexico
Study Design
- Study Type
- observational
- Observational Model
- CASE CONTROL
- Time Perspective
- PROSPECTIVE
- Sponsor Type
- OTHER
- Responsible Party
- PRINCIPAL INVESTIGATOR
- PI Title
- PhD
Study Record Dates
First Submitted
July 16, 2012
First Posted
July 18, 2012
Study Start
January 1, 2011
Primary Completion
October 1, 2011
Study Completion
July 1, 2012
Last Updated
July 18, 2012
Record last verified: 2012-07